Valuation: Sanofi

Market Cap 89.22B 103B 103B 83.04B 76.25B 144B 9,798B 146B 979B 384B 4,878B 385B 377B 16,356B P/E 2026 *
12.1x
P/E 2027 * 10.3x
Enterprise Value 101B 116B 116B 93.67B 86B 162B 11,051B 165B 1,104B 433B 5,502B 435B 425B 18,448B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.91x
Free-Float
89.21%
Yield 2026 *
5.69%
Yield 2027 * 6.04%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 103B
-2.72%-3.95%+50.70%+152.78% 1,024B
-1.72%-2.68%+53.20%+50.87% 618B
-2.25%-3.25%+28.54%+67.99% 443B
+0.11%-0.81%+40.08%+33.81% 349B
-1.64%-1.43%+33.94%+42.24% 297B
-8.81%-6.71%+7.97%+10.31% 264B
-1.93%-5.93%-1.87%-42.77% 209B
-1.84%+2.43%+29.74%+67.16% 208B
-0.83%+0.70%+15.05%+72.05% 162B
Average -2.11%-1.35%+28.59%+50.49% 397.08B
Weighted average by Cap. -2.28%-2.17%+36.90%+73.27%

Financials

2026 *2027 *
Net sales 47.44B 54.57B 54.57B 44.16B 40.54B 76.56B 5,210B 77.75B 520B 204B 2,594B 205B 200B 8,697B 50.47B 58.05B 58.05B 46.97B 43.13B 81.44B 5,542B 82.7B 554B 217B 2,759B 218B 213B 9,251B
Net income 7.78B 8.95B 8.95B 7.24B 6.65B 12.56B 854B 12.75B 85.37B 33.5B 425B 33.62B 32.88B 1,426B 9.28B 10.68B 10.68B 8.64B 7.93B 14.98B 1,019B 15.21B 102B 39.96B 507B 40.09B 39.21B 1,701B
Net Debt 11.42B 13.13B 13.13B 10.63B 9.76B 18.42B 1,254B 18.71B 125B 49.16B 624B 49.32B 48.24B 2,093B 7.38B 8.49B 8.49B 6.87B 6.3B 11.91B 810B 12.09B 80.95B 31.77B 403B 31.87B 31.17B 1,352B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA